FDA PMA
FDA Class 3
30-Day Notice Accepted
🇺🇸 United States
Implant, Dermal, For Aesthetic Use
PMA: P170002
·
Supplement: S013
·
Decision Mar 19, 2021
Classifications
1
FEI Numbers
29
Registration Numbers
29
Basic Information
- Device Name
- Implant, Dermal, For Aesthetic Use
- Trade Name
- RHA 2, RHA 3, RHA 4
- PMA Number
- P170002
- Supplement Number
- S013
- Device Class
- FDA Class 3
- Product Code
- LMH
- Generic Name
- Implant, dermal, for aesthetic use
- Medical Specialty
- Unknown
- Advisory Committee
- General, Plastic Surgery
- Decision
- 30-Day Notice Accepted
- Decision Code
- OK30
- Decision Date
- March 19, 2021
- Date Received
- February 17, 2021
- Supplement Type
- 30-Day Notice
- Supplement Reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Expedited Review
- N
Advisory Committee Statement
Declare the change of analytical laboratory in charge of the assay of sodium hyaluronate (NaHA) content in the finished products at the release step for RHA2, RHA3, and RHA4.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| LMH | Implant, Dermal, For Aesthetic Use | FDA class 3 | Unknown |